Physician profile
Joseph Augustine
NPI 1255328126
$13,031.69
in general payments reported to CMS, 2019-2025
62 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $1,438 · 2021: $1,971 · 2022: $2,299 · 2023: $2,164 · 2024: $1,961 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,283.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,518.35 | 2019-2025 | Ubrelvy, Linzess, Viberzi |
| Amgen INC. | $1,063.98 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $1,054.10 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $935.55 | 2019-2025 | |
| Lilly USA, LLC | $827.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Teva Pharmaceuticals USA, INC. | $743.81 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Amarin Pharma, INC. | $709.38 | 2019-2022 | |
| Glaxosmithkline, LLC. | $667.63 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $552.61 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $482.80 | 2022-2025 | |
| Novo Nordisk INC | $481.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $354.83 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $338.10 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $335.99 | 2022-2025 | |
| Exact Sciences Corporation | $309.64 | 2023-2025 | Cologuard Collection Kit |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Augustine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.